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A tissue microarray analysis of 22 proteins in gastrointestinal stromal tumours (GIST), followed by an unsupervised, hierarchical
monothetic cluster statistical analysis of the results, allowed us to detect a vascular endothelial growth factor (VEGF) protein
overexpression signature discriminator of prognosis in GIST, and discover novel VEGF-A DNA variants that may have functional
significance.
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The clinical behaviour of gastrointestinal stromal tumours (GIST)
is notoriously difficult to predict. The prognostic and therapeutic
significance of KIT mutations is somewhat contradictory (Ernst
et al, 1998; Lasota et al, 1999; Moskaluk et al, 1999; Taniguchi et al,
1999; Lasota et al, 2000; Hirota et al, 2001; Wardelmann et al, 2002;
Koay et al, 2005). Therefore, it appears that new molecular
indicators of prognostication are needed. Tissue microarrays
(TMA) is a high-throughput method for the analysis of large
numbers of formalin-fixed, paraffin-embedded (FFPE) materials
with minimum cost and effort (Kononen et al, 1998). Here, we
applied the TMA technology to analyse protein expression in GIST.
The results were analysed with an unsupervised, hierarchical
monothetic cluster statistical method. Those biomarkers with
strong clinical significance were tested for mutation status by both
PCR-denaturing high performance liquid chromatography
(DHPLC) and direct sequencing. By doing so, we identified a
VEGF-A protein overexpression signature as a statistically sig-
nificant predictor of malignancy, discovered VEGF-A ligand DNA
variants in GIST, and provided other possible targets in future
design of anti-VEGF-directed therapy against GIST.
MATERIALS AND METHODS
We used 50 archival paraffin blocks (Department of Pathology,
National University Hospital, Singapore), including 15 cases of
GIST with a benign outcome, 17 with a malignant outcome
(13 primary neoplasms and four metastases), 10 with no available
clinical follow-up, and eight gastrointestinal mesenchymal neoplasms
other than GIST, such as leiomyoma (n¼5), leiomyosarcoma,
neurofibroma and schwannoma (one of each). The mean clinical
follow-up was of 39 months. The overall clinico-pathological
characteristics are summarised in Table 3. No chemo or radio-
therapy was given to these patients. All the gross and histopatho-
logical parameters classically associated with malignant potential
were analysed. The findings were similar to those reported in other
series (data not shown) and, in themselves, are considered
insufficient for single-case prognostication in the clinical setting.
After case review for diagnostic confirmation, the TMA was
constructed as reported elsewhere (Zhang et al, 2003a; Salto-Tellez
et al, 2004). The 22 antibodies used are 34 BE12, AE 1/3, Bcl-2,
CAM 5.2, CD10, CD117, CD34, c-erbB2, CK7, CK20, Desmin, Flk-1,
Flt-1, Hep Par1, Ki-67, MNF 116, p53, PCNA, S100, SMA, VEGF-A
and Vimentin. Table 4 indicates the antibodies and their technical
specifications. In general, these antibodies can be divided into
several groups: diagnostic markers, antibodies expressed in a
specific differentiation pathway relevant to GIST, proliferative or
apoptosis-related markers, angiogenic proteins, and others that
may have been associated before with prognostic significance in
GIST. The interpretation of the IHC staining results for TMA was
confirmed by three independent observers (NME, LCK and MST).
Results were interpreted based on previous published experience
for each individual antibody.
The concordance between TMA and full sections, tested for five
antibodies (Table 5) ranged from 92–100% in five of six
antibodies, excluding S100 (71%), in concordance with previous
published results (Zhang et al, 2003a).
The 28 FFPE cases with available clinical follow-up were the
subject of genomic DNA extraction (GENTRA DNA Purification
Kit – Gentra, Minneapolis, MN, USA), according to the
manufacturer’s instruction. Mutation analysis was performed
by PCR-DHPLC analysis. Briefly, DNA was amplified in 25ml
reactions containing 2ml DNA template, 1ml of each forward and
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sreverse primers (10mM each), 0.5mlo f1 0m M dNTP, 0.2ml FastStart
Taq (Roche, Mannheim, Germany), and 1 PCR reaction buffer
with MgCl2. Primer sequences and cycling conditions are indicated
in Tables 6 and 7. The PCR product (8ml) was denatured at 951C
for 5min followed by gradual re-annealing to room temperature
for over a period of 1h. DHPLC was performed using a fully
automated WAVE 3500HT system (Transgenomic, Omaha, NE,
USA). The cooled samples were automatically injected into a
Table 1 Indication of the immunohistochemistry results based on the groups from the hierarchical cluster analysis (see Figure 1), and highlighting the
VEGF protein expression signature
B2
M(M6)
M4
M3
M(M5)
B1
M5
NF
M9
M10
M1
B5
B8
U1
B13
M7
M8
M11
M12
M13
U2
M(M9)
M(M2)
SCH
B3
B4
B7
U3
B6
U4
B10
B11
B12
B15
B14
U5
M6
U6
U7
M2
U8
U9
Group 1: VEGF-A expression
Group 2: VEGF-A lack of expression
Case no. VEGF-A Flt-1 Flk-1 SMA CD117 Vimentin CD34 Desmin S100
U10
B9
LM1
LMS
LM2
LM3
LM4
LM5
Group 3: Smooth muscle signal
Green indicates antibody expression, whereas red indicates lack of expression. The tumours are divided into four clinically relevant groups – GISTs that are clinically benign,
malignant and of unknown clinical outcome; and non-GISTs : LMS – leiomyosarcoma, LM – leiomyoma; NF – neurofibroma; SCH – schwannoma. Cases with brackets are
metastasis from the original tumour, the latter indicated within brackets, for example, M(M2) denotes the liver metastasis from case M2. Those antibodies not included in the
table (34 BE12, AE 1/3, CK7, CK20 and Hep Par1) were universally negative for all the samples of the study.
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sTable 2 Protein expression and sequence status of VEGF and KIT in malignant and benign GIST samples
VEGF KIT VEGF VEGF VEGF KIT
Case IHC IHC Exon 1 Exon 3 Exon 4 Exon 11
benign
1+ +
2+ + 550A:deletion 27bp
3 + + IVS1–7:C4T
4+ +
5   + IVS4–28:C4T 559C:deletion 6bp
6   + IVS4–28:C4T 572A: insertion 5bp
7   + IVS4–28:C4T
8   + 558A:deletion 9bp
9   +
10   +
11   +
12    IVS1–7:C4T
13    IVS4–28:C4T
malignant
1 + + IVS1–7:C4T
2 + + 91A:G4A(G4D) 557A:deletion 6bp
3 + + IVS4–28:C4T 550A:deletion 27bp
4+ + 550A:deletion 27bp
5+ + 557T:deletion 6bp
6+ + 558G:deletion 3bp
7+ +
8+ +
9+ +
10 + +
11 +  
12 +   IVS1–7:C4T 48A:G4T(Q4H) IVS4–28:C4T 550A:deletion 27bp
13   + IVS4–28:C4T 550A:deletion 27bp
14    IVS1–7:C4T 551C:deletion 12bp
15   
+¼expression,  ¼no expression. Sequence variants are denoted as ‘codon followed by nucleotide position (A¼1st, B¼2nd, C¼3rd): nucleotide change (protein change)’.
Non-coding variants are denoted as ‘IVS, exon, nucleotides from exon start: nucleotide change’.
Table 3 Characteristics of benign (B) and malignant (M) GISTs
No Age Site Size (mm) Cell type
Mitoses
(/50HPF)
SMA
% +ve
CD34
% +ve
CD117
% +ve
Status
(months) Metastases/recurrence
B1 45 Duod 20 s 2 0 0 100 aned (76) Nil
B2 39 Gastric 70 m 1.5 0 100 80 aned (124) Nil
B3 45 Gastric 10 s 0 0 100 95 aned (24) Nil
B4 46 Gastric 27 s 1 0 100 100 aned (20) Nil
B5 53 Gastric 29 m 0 0 80 85 aned (24) Nil
B6 69 Gastric 35 s 1 10 100 40 aned (87) Nil
B7 71 Gastric 90 s 1 0 100 100 aned (3) Nil
B8 77 Gastric 45 s 1 0 100 80 aned (68) Nil
B9 42 Gastric 50 s 3.5 0 0 0 aned (13) Nil
B10 50 Gastric 100 s 1 0 90 30 aned (10) Nil
B11 62 Gastric 6 s 1 15 100 100 aned (1) Nil
B12 87 Gastric 25 s 0 0 100 100 aned (6) Nil
B13 87 Gastric 7 s 3 0 100 100 aned (12) Nil
B14 47 Pelvic 60 s 4 0 100 100 aned (83) Nil
B15 49 Jejunal 45 s 2 0 0 100 aned (60) Nil
M1 67 Colon 90 s 15 0 100 0 dod (21) LR
M2 37 Duodenal 60 m 4.5 0 70 50 awd (89) Liver
M3 36 Gastric 180 s 62.5 0 100 100 dod (17) Liver
M4 52 Gastric 190 s 7.5 0 100 100 dod (36) No data
M5 59 Gastric 70 e 10 0 0 0 dod (72) Liver, bones, abdominal nodes
M6 71 Gastric 170 e 24 0 100 100 awd (103). Omentum, LR
M7 41 Gastric 100 e 26 0 100 75 dod (43) Retroperitoneum
M8 48 Gastric 35 s 24.5 0 100 70 dod (27) Peritoneum
M9 48 Gastric 150 s 31 0 100 100 dod (22) Liver, spleen
M10 68 Gastric 110 s 113.5 0 100 85 dod (7) Liver, LR
M11 73 Gastric 60 s 66.5 0 100 100 dod (8) No data
M12 65 Jejuno-ileal 90 s 52 45 100 100 awd (15) Peritoneum
M13 33 Rectal 60 s 0.5 2.5 100 70 duc Liver, bone, para-aortic nodes, lungs
B¼Benign cases; M¼Malignant cases; s¼spindle cell type; e epithelioid cell type; m¼mixed epithelioid and spindle cell type; aned¼alive with no evidence of disease;
awd¼alive with disease; dod¼died of disease; duc¼died of unrelated causes; LR¼local recurrence.
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sDNASep cartridge (Transgenomic) and eluted at a flow rate of
0.9mlmin
 1 through a linear gradient of acetonitrile containing
0.1 M triethylammonium acetate (TEAA). Buffer A (0.1 M TEAA
solution) and buffer B (0.1 M TEAA with 25% acetonitrile solution)
concentrations and oven temperatures for optimal heteroduplex
separation under partially DNA denaturation was determined
using the WAVE Navigator software followed by empirical
adjustment. Amplicons from the HeLa cell line were included in
each run as a wild-type reference.
Samples showing a dHPLC aberrant elution profile were re-
amplified and sequenced in both directions. Direct sequencing was
performed on the ABI PRISM Model 3100 DNA sequencer (Applied
Biosystems, Foster City, CA, USA), using the same primers as were
used for amplification. Sequencing reactions were conducted with
the ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems) according to the manufacturer’s instructions.
The monothetic cluster analysis was carried out as reported
elsewhere (Zhang et al, 2003b) Significance tests included the
student’s unpaired t-test (2-tailed) for numerical variables and the
Fisher’s exact probability test for categorical variables. Significance
value for P was taken to be Po0.05.
RESULTS
VEGF protein expression signature and its prognostic
significance in GIST
Table 1 shows the whole protein expression results. Figure 1 shows
the cluster diagram obtained upon monothetic hierarchical cluster
analysis, including IHC of representative cases. From the cluster
analysis, two main groups emerged, based on reactivity for the
VEGF-A ligand antibody. Group 1 includes all the VEGF-A ligand
expressing cases; out of the 20 GISTs with known clinical outcome,
15 were malignant (75%). In group 2 (VEGF-A negative), only 2/11
of the cases (18%) had a malignant outcome. The difference was
statistically significant (P¼0.003). Within group 2, the two
malignant cases are further subclassified into a cluster arm, which
is positive for flt-1, a receptor for VEGF. Hence, all 17/17
malignant cases were positive for either VEGF-A ligand or the
VEGF-A receptor, flt-1, as compared to 8/15 of the benign cases
(P¼0.002). In all, 13/17 malignant cases were positive for both
these markers as compared to 4/15 benign cases (P¼0.006).
Indeed, concomitant expression of VEGF ligand and VEGF receptor
Table 4 Antibodies used
Antibody Type Source Dilution
34 BE12 Monoclonal Dako, Glostrup, Denmark 1:500
AE 1/3 Monoclonal Dako, Glostrup, Denmark 1:1000
Bcl-2 Monoclonal Dako, Glostrup, Denmark 1:200
CAM 5.2 Monoclonal Becton-Dickinson, San Jose,
CA, USA
1:20
CD10 Monoclonal Novocastra, Newcastle, UK 1:200
CD117 Polyclonal Dako, Denmark 1:1000
CD34 Monoclonal Dako, Glostrup, Denmark 1:1000
c-erbB2 Monoclonal Signet Laboratories Inc.,
Dedham, MA, USA
1:200
CK7 Monoclonal Dako, Glostrup, Denmark 1:2000
CK20 Monoclonal Neomarker, Fremont, CA,
USA
1:200
Desmin Monoclonal Neomarker, Fremont, CA,
USA
1:500
Flk-1 Monoclonal Santa Cruz Biotechnology,
Santa Cruz, CA, USA
1:500
Flt-1 Monoclonal Santa Cruz Biotechnology,
Santa Cruz, CA, USA
1:1000
Hep Par1 Monoclonal Dako, Glostrup, Denmark 1:500
Ki-67 Monoclonal Dako, Glostrup, Denmark 1:100
MNF 116 Monoclonal Dako, Glostrup, Denmark 1:500
p53 Monoclonal Dako, Glostrup, Denmark 1:500
PCNA Monoclonal Dako, Glostrup, Denmark 1:1000
S100 Polyclonal Dako, Glostrup, Denmark 1:10000
SMA Monoclonal Dako, Glostrup, Denmark 1:1000
VEGF-A Monoclonal Santa Cruz Biotechnology,
Santa Cruz, CA, USA
1:500
Vimentin Monoclonal Dako, Glostrup, Denmark 1:1000
Table 5 Comparison of results of TMA vs full section analysis
SMA Vim CAM5.2 CD117 CD34 S100
Full sections + 14 47 3 39 37 17
  37 4 48 12 14 34
TMA + 14 47 1 35 34 4
  37 4 50 16 17 47
Disagree 4 0 2 4 3 15
Concordance % 92 100 96 92 94 71
Table 6 KIT PCR conditions
Exon Forward primer Reverse primer Size (bp) Tm (1C)
DHPLC
temperature (1C) DHPLC gradient
95 0ATGCTCTGCTTCTGTACTGCC300 CAGAGCCTAAACATCCCCTTA30 185 60 57 47.5–61.5%B in 4.5min
11 50CCAGAGTGCTCTAATGACTG30 50ACCCAAAAAGGTGACATGGA30 184 60 56 47.5–61.5%B in 4.5min
13 50CATCAGTTTGCCAGTTGTGC30 50ACACGGCTTTACCTCCAATG30 142 60 59 44.2–58.2%B in 4.5min
17 50TGTATTCACAGAGACTTGGC30 50GGATTTACATTATGAAAGTCACAGG30 172 55 56 46.7–60.7%B in 4.5min
Table 7 VEGF-A PCR conditions
Exon Forward primer Reverse primer Size (bp) Temperature (1C)
Oven
temperature (1C)
Buffer
concentration (%B)
1 GGGGAGGAAGAGTAGCTCG GCACCTAAGACGACAGAGGG 324 60 66.8 55.4
2 CTGTTGGTGGGAGGGAAGTG AAGGAATTAGGCCATCCACC 224 65 63.0 47
3 GCTAGCCATCTTTTGTGTCG TGTTCCCAAAGTGTTACCCC 314 65 61.8 55.1
4 GGTTGTCCCATCTGGGTATG TAACCCTGGCACAGATCAGG 210 65 60.9 46.3
5 TCACCATCTTAACCCTTCCC ACAGAGGTAGCCAAGAGCCC 161 65 60.7 39
6 CCTGCCCACCTTACCACTTC GAGGCTCCAGGGCATTAGAC 188 65 60.8 41
7 CAGCTGCGGACATGTTAGG TCGCTCGCTCACTCTCTTTC 313 65 59.8 55.1
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srepresents a VEGF-A protein expression signature in GIST with
obvious clinical significance. Lastly, proliferation and oncogenic-
related markers PCNA, Ki-67/MIB, bcl-2 and p53 showed no
statistically significant preference in reactivity for malignant GISTs
(P40.05). The fact that all the smooth muscle lesions included in
the analysis are clustering in a separate group (group 3) is a
measure of the robustness of this analytical approach.
New VEGF-A variants are discovered as a result of
mutation analysis
Those GIST samples with known clinical follow-up underwent
genomic analysis. In view of the evidence of KIT mutations in GIST
and their possible prognostic value (as well as their relation to
imatinib therapeutic response) (Lasota et al, 1999; Heinrich et al,
2003), exons 9, 11, 13, 17 of KIT (which are those related to
prognosis in the literature) were analysed in the same methodo-
logical manner. The results are summarised in Table 2. Variants
identified included non-coding IVS1–7:C-T changes in five
(18%) samples (Figure 2), IVS4–28:C-T changes in seven (25%)
samples and coding codon 48A:G-T( Q -H) and codon 91A:G-
A( G -D) changes in one sample each (Table 2). A total of 12
(43%) cases had variants in KIT, all in exon 11 (Figure 3). VEGF
IVS4–28:C-T variants were more frequent in samples with
low (5/7, 71%) than high (2/7, 29%) VEGF-A expression. The
VEGF codon 48 and 91 mutants were present in samples with high
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Figure 1 In red are the study cases with malignant behaviour, in blue are those cases with benign behaviour; cases without available follow-up and non-
GISTs are in black. The TMA immunohistochemistry results are included. The asterisk indicates cases reflected in the photomicrographs. Other abbreviations
are similar to those described in Table 1. VEGF1 is equivalent to VEGF-A in this figure.
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sVEGF-A expression, KIT mutations and of a malignant phenotype.
KIT mutations were more frequent in samples with high (10/22,
46%) than low (2/6, 21%) KIT expression. Nevertheless, none of
the associations between sequence variants and the expression
of their respective proteins, or with the presence of each other,
were significant, presumably due to the limited number of
samples in this series. The only parameter significantly associa-
ted with malignancy in these selected 28 cases was, as expected,
VEGF-A protein expression (P¼0.020). Of interest, there was
no association with exon 11 KIT mutations and survival in our
series.
DISCUSSION
The uncertain prognosis of GIST, both before (Nilsson et al,
2005) and after (Kosmadakis et al, 2005) imatinib treatment,
indicate the need for the search of other molecular prognostication
biomarkers.
GIST are highly vascularised neoplasms and VEGF-A is a major
antiangiogenic therapeutic target (Ferrara and Kerbel, 2005).
Recently, anti-VEGF-A therapy has been successful in the
treatment of GIST (Marx 2005), with drugs such as Sutent and
Sorafenib. Our results indicate that a combined VEGF-A ligand-
receptor protein expression signature is a determinant of clinical
behaviour in GIST. This is obvious in our study because (a) there
is a relation between protein overexpression of the VEGF-A ligand
and Flt-1 proteins and benign/malignant behaviour; (b) novel
variants in the VEGF-A ligand gene are characterised, some of
which appear related to a malignant behaviour (such as VEGF-A
exon 3); and (c) in general, these VEGF-ligand variants localise to
areas of the VEGF protein with functional significance. The role of
flt-1 in this context is unclear; it could be related to the induction
of metalloproteinases (Hiratsuka et al, 2002), or to chemotactic
signals (Wey et al, 2005).
The role of the detected VEGF-A ligand variants in protein
overexpression and GIST tumorigenesis can only be a matter of
speculation, based on the scant information available. The IVS4–
28:C-T variant is also identified in phenotypically normal
gastrointestinal tissue, thus may not be relevant. The two other
variants, however, may have functional implications. The IVS1–
7:C-T variant lies within a GC box that binds the transcriptional
repressor protein methyl CpG binding protein-2 (Lapchak et al,
2004), and was found to be associated with higher levels of VEGF
mRNA in colorectal cancer (Yamamori et al, 2004), increasing the
risk of liver metastasis and worsening its prognosis. In addition,
two missense mutations (unreported to date) were discovered in
exon 3, coding codon 48A:G-T( Q -H) and codon 91A:G-A
(G-D), both in malignant GIST and both showing VEGF-A ligand
protein overexpression. In any case, the evidence points to the
novel hypothesis that VEGF-A ligand mutations may play a role if
the biology and prognosis of GIST.
There has been a previous suggestion that VEGF-A ligand
protein expression may be related to prognosis (Takahashi et al,
2003). However, the strength of our unsupervised hierarchical
cluster analysis, comparing the expression of an antibody in the
context of another 21 biomarkers, delineates ‘biological groups’
and establishes more complete ‘prognostic signatures’, which in
our study, shown the importance of including protein expression
of both VEGF-A ligand and flt-1 receptor in the characterisation of
malignant behaviour.
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